This case is a supplement to Imprimis (Case A), Imprimis (Case B), and Imprimis (Case C). It describes Imprimis's 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750/pill. Imprimis also created compounded alternatives to several other branded drugs, and made investments to increase its manufacturing capabilities. The company now had to decide where to focus its efforts in the future. In developing innovative compounded formulations, should it base its decisions on market size, either by population or dollar size? Should it concentrate instead on the level of exploitation by the branded drug manufacturers--how much they had raised prices by, in what amount of time? Or should it decide instead based on the life-threatening nature of the disease, regardless of how many people were afflicted? The company had to balance these choices with the expansion of its core ophthalmology business while continuing to raise funds from investors.

【書誌情報】

ページ数：3ページ

サイズ：A4

商品番号：HBSP-717498

発行日：2017/4/3

登録日：2017/10/12